EntryPoint Capital LLC Invests $420,000 in 10x Genomics $TXG

Key Points

• EntryPoint Capital LLC made a new investment of $420,000 in 10x Genomics (NASDAQ: TXG), purchasing 48,137 shares.
• Several hedge funds increased their stakes in 10x Genomics during the fourth quarter, with notable increases from LPL Financial LLC (26.2%) and Russell Investments Group Ltd. (70.1%).
• Analysts have mixed ratings on the stock, with a consensus "Hold" rating and an average price target of $13.54, though prices range significantly from $6.50 to $15.00 among different firms' assessments.

EntryPoint Capital LLC purchased a new position in shares of 10x Genomics (NASDAQ:TXG - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 48,137 shares of the company's stock, valued at approximately $420,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in TXG. RA Capital Management L.P. bought a new stake in shares of 10x Genomics during the fourth quarter worth about $47,092,000. D. E. Shaw & Co. Inc. bought a new stake in shares of 10x Genomics during the fourth quarter worth about $17,499,000. Two Sigma Investments LP grew its holdings in shares of 10x Genomics by 291.2% during the fourth quarter. Two Sigma Investments LP now owns 1,319,487 shares of the company's stock worth $18,948,000 after purchasing an additional 982,203 shares during the last quarter. ARK Investment Management LLC grew its holdings in shares of 10x Genomics by 7.5% during the first quarter. ARK Investment Management LLC now owns 12,845,713 shares of the company's stock worth $112,143,000 after purchasing an additional 901,656 shares during the last quarter. Finally, Two Sigma Advisers LP grew its holdings in shares of 10x Genomics by 240.6% during the fourth quarter. Two Sigma Advisers LP now owns 1,236,200 shares of the company's stock worth $17,752,000 after purchasing an additional 873,200 shares during the last quarter. 84.68% of the stock is currently owned by institutional investors.

10x Genomics Stock Down 0.7%

TXG traded down $0.10 during trading on Tuesday, hitting $13.97. The company's stock had a trading volume of 309,334 shares, compared to its average volume of 3,401,585. 10x Genomics has a twelve month low of $6.78 and a twelve month high of $24.76. The stock's fifty day moving average price is $12.65 and its 200-day moving average price is $10.62. The firm has a market capitalization of $1.74 billion, a P/E ratio of -19.93 and a beta of 2.03.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.63. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.The company had revenue of $172.91 million for the quarter, compared to analyst estimates of $139.36 million. During the same period in the prior year, the firm earned ($0.32) earnings per share. 10x Genomics's revenue for the quarter was up 12.9% on a year-over-year basis. 10x Genomics has set its Q3 2025 guidance at EPS. Equities research analysts expect that 10x Genomics will post -1.43 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on TXG. UBS Group boosted their price target on 10x Genomics from $12.00 to $13.00 and gave the stock a "neutral" rating in a report on Friday, August 8th. Barclays restated an "overweight" rating and issued a $15.00 price target (up previously from $13.00) on shares of 10x Genomics in a research report on Friday, August 8th. Weiss Ratings restated a "sell (e+)" rating on shares of 10x Genomics in a research report on Thursday, August 14th. JPMorgan Chase & Co. dropped their price target on shares of 10x Genomics from $12.00 to $9.00 and set a "neutral" rating on the stock in a research report on Friday, May 9th. Finally, Morgan Stanley dropped their price target on shares of 10x Genomics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 12th. Six analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, 10x Genomics has a consensus rating of "Hold" and an average price target of $13.54.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.